Entering text into the input field will update the search result below

Adamis Pharmaceuticals: It's Now Or Never


  • Adamis Pharmaceuticals has two FDA-approved products and a potential blockbuster drug in TEMPOL. However, the company has a long history of blunders that have devastated the share price.
  • I believe the company has a chance to make 2022 a turnaround year, but it is going to require making deals and not excuses to get investors reinvigorated about ADMP.
  • I discuss some of the leading downside risks that investors should be aware of.
  • Finally, I reveal my plan for trading ADMP through the rest of 2021 and throughout 2022.

Coronavirus and DNA, virus mutation. New variant and strain of SARS CoV 2. Microscopic view.

Gilnature/iStock via Getty Images

Adamis Pharmaceuticals (NASDAQ:ADMP) recently received FDA approval for its intramuscular injection naloxone product ZIMHI. This approval has been a long time coming and is the company's second marketed product using their platform. Both of these products

This article was written by

Biologics profile picture
Diagnosing the market to compound capital in the healthcare sector.

After years of working in the medical field, I have developed a passion for biotech and lifesaving therapies. Now, I am a full-time healthcare investor who is in search of the next breakthrough therapy, device, or pharmaceutical. My trade focus is around catalysts and potential acquisitions. In addition, I provide a marketplace service, Compounding Healthcare through Seeking Alpha.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of ADMP either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.